23andMe Launches New Genetic Report on Osteoporosis
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...
23andMe Considers Sale as Cash Runs Low
The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.
newsbytesapp.com2d
23andMe considers sale amid financial struggles and leadership turmoil
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
Nature9d
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
Stocks to Watch: 23andMe, Manhattan Associates, Nextracker
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...